Literature DB >> 8610959

Tamoxifen-induced steatohepatitis.

M Van Hoof, J Rahier, Y Horsmans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8610959     DOI： 10.7326/0003-4819-124-9-199605010-00015

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

1.  Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women.

Authors:  Masahide Hamaguchi; Takao Kojima; Akihiro Ohbora; Noriyuki Takeda; Michiaki Fukui; Takahiro Kato
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

2.  Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice.

Authors:  Y Nemoto; K Toda; M Ono; K Fujikawa-Adachi; T Saibara; S Onishi; H Enzan; T Okada; Y Shizuta
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

3.  Customizable Microfluidic Origami Liver-on-a-Chip (oLOC).

Authors:  Xin Xie; Sushila Maharjan; Chastity Kelly; Tian Liu; Robert J Lang; Roger Alperin; Shikha Sebastian; Diana Bonilla; Sakura Gandolfo; Yasmine Boukataya; Seyed Mohammad Siadat; Yu Shrike Zhang; Carol Livermore
Journal:  Adv Mater Technol       Date:  2021-11-30

4.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Authors:  Savino Bruno; Patrick Maisonneuve; Paola Castellana; Nicole Rotmensz; Sonia Rossi; Marco Maggioni; Marcello Persico; Alberto Colombo; Franco Monasterolo; Donata Casadei-Giunchi; Franco Desiderio; Tommaso Stroffolini; Virgilio Sacchini; Andrea Decensi; Umberto Veronesi
Journal:  BMJ       Date:  2005-03-03

5.  Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice.

Authors:  Tetsu Egawa; Katsumi Toda; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisaw; Toshiji Saibara; Yoshihiro Hayashi; Makoto Hiroi; Hideaki Enzan; Saburo Onishi
Journal:  Lipids       Date:  2003-05       Impact factor: 1.880

Review 6.  Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.

Authors:  Ichiro Shimizu; Nao Kohno; Katsuyoshi Tamaki; Masayuki Shono; Hui-Wei Huang; Jiang-Hong He; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

7.  The influence of metabolic factors for nonalcoholic Fatty liver disease in women.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Seon Hee Lim; Jong In Yang; Young Sun Kim; Sun Young Yang; Min-Sun Kwak; Joo Sung Kim; Sang-Heon Cho
Journal:  Biomed Res Int       Date:  2015-04-20       Impact factor: 3.411

Review 8.  Current treatment paradigms and emerging therapies for NAFLD/NASH.

Authors:  Sana Raza; Sangam Rajak; Aditya Upadhyay; Archana Tewari; Rohit Anthony Sinha
Journal:  Front Biosci (Landmark Ed)       Date:  2021-01-01

Review 9.  NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment.

Authors:  Johanna K DiStefano
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.